Samuel Denmeade

Samuel Denmeade at Johns Hopkins developed the concept of bipolar androgen therapy (BAT) for castration-resistant prostate cancer, exploiting supraphysiologic testosterone to sensitize AR-overexpressing tumors to subsequent enzalutamide. His TRANSFORMER and SEA-BCMA trials have demonstrated clinical efficacy and validated the mechanistic hypothesis underlying BAT. His laboratory pioneered the supraphysiologic testosterone paradox in prostate cancer biology. His innovative approach has opened a new therapeutic avenue for mCRPC that challenges conventional wisdom about androgen suppression.